Literature DB >> 3011861

Treatment of verapamil toxicity in intact dogs.

R Gay, S Algeo, R Lee, M Olajos, E Morkin, S Goldman.   

Abstract

The treatment of verapamil toxicity was examined in lightly sedated dogs. Verapamil, administered as a bolus (0.72 mg/kg) followed by a continuous infusion (0.11 mg/kg per min), decreased cardiac output (CO) from 3.1 +/- 0.1 to 1.7 +/- 0.1 liter/min (P less than 0.001), heart rate (HR) from 85 +/- 4 to 57 +/- 3 beats/min (P less than 0.001), left ventricular derivative of pressure with respect to time (LV dP/dt) from 2,085 +/- 828 to 783 +/- 78 mm Hg/s (P less than 0.001), mean aortic pressure (AO) from 77 +/- 4 to 38 +/- 2 mm Hg (P less than 0.001) and stroke volume from 39 +/- 3 to 28 +/- 2 ml/beat (P less than 0.01). In verapamil-toxic animals isoproterenol increased HR, CO, LV dP/dt, and AO; calcium chloride increased LV dP/dt and AO; norepinephrine, epinephrine, and dopamine increased CO, AO, and LV dP/dt, atropine increased HR, CO, and AO. Phenylephrine (13-55 micrograms/kg per min) produced no changes except a small increase in AO while very high dose phenylephrine (300 micrograms/kg per min) increased AO, CO, and LV dP/dt. 4-Aminopyridine (4-AP) increased HR, CO, LV dP/dt, and AO. When administered prior to verapamil, 4-AP prevented the development of verapamil toxicity as shown by the significantly higher AO (P less than 0.001), CO (P less than 0.01), and LV dP/dt (P less than 0.01) when 4-AP followed by verapamil was compared to verapamil alone. In conclusion, there does not appear to be a single specific therapy for verapamil toxicity, however it can be partially corrected by presently available pharmacologic therapy and 4-AP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011861      PMCID: PMC370537          DOI: 10.1172/JCI112505

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals.

Authors:  H Lundh; S Thesleff
Journal:  Eur J Pharmacol       Date:  1977-04-21       Impact factor: 4.432

Review 2.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  Effect of verapamil on the sinoatrial and atrioventricular nodes of the rabbit and the mechanism by which it arrests reentrant atrioventricular nodal tachycardia.

Authors:  A L Wit; P F Cranefield
Journal:  Circ Res       Date:  1974-09       Impact factor: 17.367

4.  Myocardial alpha adrenergic receptors and their role in the production of a positive inotropic effect by sympathomimetic agents.

Authors:  W C Govier
Journal:  J Pharmacol Exp Ther       Date:  1968-01       Impact factor: 4.030

5.  Effect of verapamil on the noraml action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers.

Authors:  P F Cranefield; R S Aronson; A L Wit
Journal:  Circ Res       Date:  1974-02       Impact factor: 17.367

6.  Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog.

Authors:  D P Zipes; J C Fischer
Journal:  Circ Res       Date:  1974-02       Impact factor: 17.367

7.  Fatal acute intoxication with verapamil.

Authors:  J van der Meer; E van der Wall
Journal:  Neth J Med       Date:  1983       Impact factor: 1.422

8.  Subcellular myocardial effects of verapamil and D600: comparison with propranolol.

Authors:  A M Watanabe; H R Besch
Journal:  J Pharmacol Exp Ther       Date:  1974-11       Impact factor: 4.030

9.  Alpha-1 adrenergic control of the venous circulation in intact dogs.

Authors:  C Appleton; M Olajos; E Morkin; S Goldman
Journal:  J Pharmacol Exp Ther       Date:  1985-06       Impact factor: 4.030

10.  Hemodynamic profiles of methoxamine and B-HT 933 in spinalized ganglion-blocked dogs.

Authors:  P Zandberg; P B Timmermans; P A van Zwieten
Journal:  J Cardiovasc Pharmacol       Date:  1984 Mar-Apr       Impact factor: 3.105

View more
  7 in total

1.  Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning.

Authors:  Andis Graudins; Kathy Ka Ling Wong
Journal:  J Med Toxicol       Date:  2010-06

Review 2.  4-aminopyridine toxicity: a case report and review of the literature.

Authors:  Andrew M King; Nathan B Menke; Kenneth D Katz; Anthony F Pizon
Journal:  J Med Toxicol       Date:  2012-09

Review 3.  Management of calcium channel antagonist overdose.

Authors:  Steven D Salhanick; Michael W Shannon
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Effect of levosimendan in experimental verapamil-induced myocardial depression.

Authors:  Jouni Kurola; Heli Leppikangas; Jarkko Magga; Leena Lindgren; Vesa Kiviniemi; Juha Rutanen; Esko Ruokonen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-03-11       Impact factor: 2.953

Review 5.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

6.  Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.

Authors:  Maude St-Onge; Kurt Anseeuw; Frank Lee Cantrell; Ian C Gilchrist; Philippe Hantson; Benoit Bailey; Valéry Lavergne; Sophie Gosselin; William Kerns; Martin Laliberté; Eric J Lavonas; David N Juurlink; John Muscedere; Chen-Chang Yang; Tasnim Sinuff; Michael Rieder; Bruno Mégarbane
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

Review 7.  Treatment for calcium channel blocker poisoning: a systematic review.

Authors:  M St-Onge; P-A Dubé; S Gosselin; C Guimont; J Godwin; P M Archambault; J-M Chauny; A J Frenette; M Darveau; N Le Sage; J Poitras; J Provencher; D N Juurlink; R Blais
Journal:  Clin Toxicol (Phila)       Date:  2014-10-06       Impact factor: 4.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.